<p>MDxHealth SA（納斯達克代碼：MDXH - 獲取免費報告）在 12 月份的空頭頭寸顯著增長。截至 12 月 31 日，空頭頭寸總計 39,441 股，比 12 月 15 日的 15,027 股增長了 162.5%。根據 115,122 股的平均交易量，當前的覆蓋天數比率為 0.3 天。目前，公司 0.1% 的股份被賣空。目前，公司 0.1% 的股份被賣空。根據 115,122 股的平均交易量，當前的覆蓋天數比率為 0.3 天。</p>
<h2>MDxHealth 價格表現</h2>
<p>納斯達克 MDXH 週三開盤價為 3.61 美元。該股票的 50 日移動平均線為 3.56 美元，200 日移動平均線為 3.49 美元。MDxHealth 的年內最低價為 1.35 美元，年內最高價為 5.33 美元。該公司的市值為 1.7072 億美元，市盈率為-5.64，貝塔值為 1.62。</p>
<p>MDxHealth（納斯達克代碼：MDXH - 獲取免費報告）最近一次公佈財報是在 11 月 12 日，報告顯示該季度每股收益為（0.16 美元），低於市場共識預期的（0.12 美元）4 美分。該季度的收入為 2743 萬美元，而分析師預期為 2411 萬美元。MDxHealth 的股本回報率為-1,078.01%，淨利潤率為-30.50%。股票分析師預計 MDxHealth 在當前年度的每股收益為-1.15 美元。</p>
<h2>MDxHealth 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近調整了對 MDXH 的持股。FreeGulliver LLC 在第二季度新購入 MDxHealth 的股份，價值約 273,000 美元。Calamos Advisors LLC 在第三季度購買了 MDxHealth 的新股份，價值約 305,000 美元。GSA Capital Partners LLP 在第三季度新購入 MDxHealth 的股份，價值約 48,000 美元。Jefferies Financial Group Inc.在第三季度新購入 MDxHealth 的股份，價值約 53,000 美元。最後，Russell Investments Group Ltd.在第三季度新購入 MDxHealth 的股份，價值約 461,000 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家券商對 MDXH 進行了評估。TD Cowen 在 11 月 13 日的報告中將 MDxHealth 的目標價從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。Lake Street Capital 在 11 月 13 日的研究報告中將 MDxHealth 的目標價從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 12 月 23 日的報告中重申了對 MDxHealth 的 “買入” 評級，並給出了 7.00 美元的目標價。最後，Weiss Ratings 在 12 月 29 日的報告中重申了對 MDxHealth 的 “賣出（d-）” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 7.75 美元。</p>
<p><strong>查看我們最新的 MDXH 股票分析</strong></p>
<h2>關於 MDxHealth</h2>
<p>（獲取免費報告）</p>
<p>MDxHealth 總部位於比利時梅赫倫，在美國馬薩諸塞州牛頓設有辦事處，是一家分子診斷公司，專注於通過表觀遺傳生物標誌物檢測提高癌症診斷和治療決策的準確性。該公司專注於開發和商業化檢測與泌尿系統癌症相關的 DNA 甲基化變化的測試，從而實現更精確的風險分層和患者管理。</p>
<p>MDxHealth 的主要產品組合包括 ConfirmMDx 和 SelectMDx。</p>
<h2>相關文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MDxHealth</li>
<li>埃隆將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>將這些代碼輸入您的普通經紀賬户</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
<li>股票即將迎來 “凶兆日”...</li>
<li>崩盤前一個月</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
<p>在考慮 MDxHealth 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買...而 MDxHealth 並不在名單上。</p>
<p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXH

<p>MDxHealth SA (NASDAQ:MDXH) 在 12 月份的空頭頭寸顯著增加，增長了 162.5%，達到 39,441 股。當前的空頭頭寸比率為 0.3 天，賣空股份佔 0.1%。該股票開盤價為 3.61 美元，市值為 1.7072 億美元，市盈率為-5.64。分析師的評級意見不一，普遍評級為 “適度買入”，平均目標價為 7.75 美元。該公司專注於癌症診斷和治療的分子診斷</p>

<p>MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 39,441 shares, a growth of 162.5% from the December 15th total of 15,027 shares. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.1% of the company's shares are sold short. Currently, 0.1% of the company's shares are sold short. Based on an average trading volume of 115,122 shares, the days-to-cover ratio is presently 0.3 days.</p>
<div class="lb-trans"><p>MDxHealth SA（納斯達克代碼：MDXH - 獲取免費報告）在 12 月份的空頭頭寸顯著增長。截至 12 月 31 日，空頭頭寸總計 39,441 股，比 12 月 15 日的 15,027 股增長了 162.5%。根據 115,122 股的平均交易量，當前的覆蓋天數比率為 0.3 天。目前，公司 0.1% 的股份被賣空。目前，公司 0.1% 的股份被賣空。根據 115,122 股的平均交易量，當前的覆蓋天數比率為 0.3 天。</p>
</div><h2>MDxHealth Price Performance</h2>
<div class="lb-trans"><h2>MDxHealth 價格表現</h2>
</div><p>NASDAQ MDXH opened at $3.61 on Wednesday. The stock's 50-day moving average is $3.56 and its 200-day moving average is $3.49. MDxHealth has a one year low of $1.35 and a one year high of $5.33. The firm has a market cap of $170.72 million, a P/E ratio of -5.64 and a beta of 1.62.</p>
<div class="lb-trans"><p>納斯達克 MDXH 週三開盤價為 3.61 美元。該股票的 50 日移動平均線為 3.56 美元，200 日移動平均線為 3.49 美元。MDxHealth 的年內最低價為 1.35 美元，年內最高價為 5.33 美元。該公司的市值為 1.7072 億美元，市盈率為-5.64，貝塔值為 1.62。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Equities analysts anticipate that MDxHealth will post -1.15 EPS for the current year.</p>
<div class="lb-trans"><p>MDxHealth（納斯達克代碼：MDXH - 獲取免費報告）最近一次公佈財報是在 11 月 12 日，報告顯示該季度每股收益為（0.16 美元），低於市場共識預期的（0.12 美元）4 美分。該季度的收入為 2743 萬美元，而分析師預期為 2411 萬美元。MDxHealth 的股本回報率為-1,078.01%，淨利潤率為-30.50%。股票分析師預計 MDxHealth 在當前年度的每股收益為-1.15 美元。</p>
</div><h2>Institutional Trading of MDxHealth</h2>
<div class="lb-trans"><h2>MDxHealth 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of MDXH. FreeGulliver LLC acquired a new position in shares of MDxHealth during the second quarter worth about $273,000. Calamos Advisors LLC bought a new stake in MDxHealth in the 3rd quarter valued at approximately $305,000. GSA Capital Partners LLP acquired a new position in MDxHealth during the 3rd quarter worth approximately $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the 3rd quarter worth approximately $53,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of MDxHealth in the third quarter valued at approximately $461,000.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近調整了對 MDXH 的持股。FreeGulliver LLC 在第二季度新購入 MDxHealth 的股份，價值約 273,000 美元。Calamos Advisors LLC 在第三季度購買了 MDxHealth 的新股份，價值約 305,000 美元。GSA Capital Partners LLP 在第三季度新購入 MDxHealth 的股份，價值約 48,000 美元。Jefferies Financial Group Inc.在第三季度新購入 MDxHealth 的股份，價值約 53,000 美元。最後，Russell Investments Group Ltd.在第三季度新購入 MDxHealth 的股份，價值約 461,000 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several brokerages have weighed in on MDXH. TD Cowen boosted their price objective on MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 13th. Lake Street Capital boosted their price target on shares of MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. BTIG Research restated a &#34;buy&#34; rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of MDxHealth in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $7.75.</p>
<div class="lb-trans"><p>幾家券商對 MDXH 進行了評估。TD Cowen 在 11 月 13 日的報告中將 MDxHealth 的目標價從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。Lake Street Capital 在 11 月 13 日的研究報告中將 MDxHealth 的目標價從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 12 月 23 日的報告中重申了對 MDxHealth 的 “買入” 評級，並給出了 7.00 美元的目標價。最後，Weiss Ratings 在 12 月 29 日的報告中重申了對 MDxHealth 的 “賣出（d-）” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，平均目標價為 7.75 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on MDXH</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MDXH 股票分析</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>關於 MDxHealth</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.</p>
<div class="lb-trans"><p>MDxHealth 總部位於比利時梅赫倫，在美國馬薩諸塞州牛頓設有辦事處，是一家分子診斷公司，專注於通過表觀遺傳生物標誌物檢測提高癌症診斷和治療決策的準確性。該公司專注於開發和商業化檢測與泌尿系統癌症相關的 DNA 甲基化變化的測試，從而實現更精確的風險分層和患者管理。</p>
</div><p>MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.</p>
<div class="lb-trans"><p>MDxHealth 的主要產品組合包括 ConfirmMDx 和 SelectMDx。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>“Ominous day” coming to stocks…</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MDxHealth</li>
<li>埃隆將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>將這些代碼輸入您的普通經紀賬户</li>
<li>崩盤已經開始（大多數人還未察覺）</li>
<li>股票即將迎來 “凶兆日”...</li>
<li>崩盤前一個月</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MDxHealth 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買...而 MDxHealth 並不在名單上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MDxHealth SA（NASDAQ:MDXH）空頭頭寸顯著增加